Faeth Therapeutics Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • FTH

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $8.70
  • (As of Wednesday Closing)

Faeth Therapeutics General Information

Description

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Contact Information

Formerly Known As
Panacea Pharmaceuticals, Sensei Biotherapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1405 Research Boulevard
  • Suite 125
  • Rockville, MD 20850
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1405 Research Boulevard
  • Suite 125
  • Rockville, MD 20850
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Faeth Therapeutics Stock Performance

As of 18-Nov-2026, Faeth Therapeutics’s stock price is $8.70. Its current market cap is $225M with 25.8M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.70 $9.04 $7.45 - $42.14 $225M 25.8M 498K -$22.50

Faeth Therapeutics Financials Summary

As of 30-Sep-2026, Faeth Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 589,412 (9,562) (30,206) (47,944)
Revenue 0 0 0 0
EBITDA (215,898) (22,153) (31,295) (36,981)
Net Income (211,358) (21,085) (30,157) (34,101)
Total Assets 178,949 22,902 45,361 74,374
Total Debt 145 1,509 3,845 6,208
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Faeth Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Faeth Therapeutics‘s full profile, request access.

Request a free trial

Faeth Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Faeth Therapeutics‘s full profile, request access.

Request a free trial

Faeth Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients throu
Drug Discovery
Rockville, MD
29 As of 2026

San Diego, CA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Faeth Therapeutics Competitors (69)

One of Faeth Therapeutics’s 69 competitors is Kura Oncology, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kura Oncology Formerly VC-backed San Diego, CA
Altimmune Formerly VC-backed Gaithersburg, MD
Xenetic Biosciences Corporation Framingham, MA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 69 competitors. Get the full list »

Faeth Therapeutics Patents

Faeth Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200390902-A1 Antibody-drug conjugates targeted at human aspartyl-(asparaginyl)-b-hydroxylase (haah) Inactive 22-Aug-2017
WO-2019040537-A1 Antibody-drug conjugates targeted at human aspartyl-(asparaginyl)-b-hydroxylase (haah) Inactive 22-Aug-2017
US-20190049455-A1 Haah and mmp-9 are complementary cancer biomarkers and predictors of metastasis when combined Inactive 11-Aug-2017
WO-2019032742-A1 Haah and mmp-9 are complementary cancer biomarkers and predictors of metastasis when combined Inactive 11-Aug-2017
WO-2019032744-A1 Haah and mmp-9 are complementary cancer biomarkers and predictors of metastasis when combined Inactive 11-Aug-2017 G01N33/57585
To view Faeth Therapeutics’s complete patent history, request access »

Faeth Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Faeth Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Faeth Therapeutics‘s full profile, request access.

Request a free trial

Faeth Therapeutics Acquisitions (2)

Faeth Therapeutics’s most recent deal was a Merger/Acquisition with Faeth for . The deal was made on 17-Feb-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Faeth 17-Feb-2026 Merger/Acquisition Drug Discovery
Alvaxa Biosciences 19-May-2020 Merger/Acquisition Biotechnology
To view Faeth Therapeutics’s complete acquisitions history, request access »

Faeth Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.47 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Faeth Therapeutics’s complete esg history, request access »

Faeth Therapeutics FAQs

  • When was Faeth Therapeutics founded?

    Faeth Therapeutics was founded in 1999.

  • Where is Faeth Therapeutics headquartered?

    Faeth Therapeutics is headquartered in Rockville, MD.

  • What is the size of Faeth Therapeutics?

    Faeth Therapeutics has 29 total employees.

  • What industry is Faeth Therapeutics in?

    Faeth Therapeutics’s primary industry is Drug Discovery.

  • Is Faeth Therapeutics a private or public company?

    Faeth Therapeutics is a Public company.

  • What is Faeth Therapeutics’s stock symbol?

    The ticker symbol for Faeth Therapeutics is FTH.

  • What is the current stock price of Faeth Therapeutics?

    As of 18-Nov-2026 the stock price of Faeth Therapeutics is $8.70.

  • What is the current market cap of Faeth Therapeutics?

    The current market capitalization of Faeth Therapeutics is $225M.

  • Who are Faeth Therapeutics’s competitors?

    Kura Oncology, Altimmune, Xenetic Biosciences, Sarepta Therapeutics, and Immunocore Holdings are some of the 69 competitors of Faeth Therapeutics.

  • What is Faeth Therapeutics’s annual earnings per share (EPS)?

    Faeth Therapeutics’s EPS for 12 months was -$22.50.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process